DRUG THERAPY OF BREAST CANCER PATIENTS WITH METASTATIC BRAIN LESIONS.

The Blokhin RCRC the effectiveness of various schemes of drug therapy in breast cancer patients with brain metastases was evaluated.

When using the schemes with anthracyclines (CAF, AC) among 26 patients objective response in the brain (full and partial regression) was registered in 16 (62%) patients (previously untreated patients). Median survival was 12 months. In the group of patients received monotherapy (30 patients), capecitabine was administered at a dose of 2000 mg/m2/day per os the 1 to 14 days every 3 weeks. Partial effect in the brain was registered in 9 patients (30%). Median survival was 15.1 months. In the combination therapy group (capecitabine + radiotherapy) among 30 patients overall effect in the brain was registered in 4 patients (13%), partial response - 18 (60%). Median survival was 22 months. The effectiveness of chemotherapy scheme gemcitabine and cisplatin in 30 breast cancer patients with metastases in the brain, previously treated with I-III line of chemotherapy and radiation therapy in the area of the brain was evaluated. In 4 cases (13.3%) complete regression of metastases in the brain was achieved. In 12 patients (40.0%) a partial regression of metastases in the brain was achieved. Median survival was 10 months. Twenty-three breast cancer patients with overexpression of Her2/neu, and with metastatic brain lesions received capecitabine + lapatinib. Complete response in the brain was achieved in 2 cases (8.7%), partial regression - in 9 cases (39.1%) and stabilization of the disease - in 10 cases (43.5%). Median overall survival was 16 months. Nine patients with breast cancer with overexpression of Her2/neu, and with metastatic brain lesions received therapy with capecitabine + trastuzumab. In 2 cases (22.2%) complete regression of metastases in the brain was achieved, in 4 cases (44.4%) - partial response, in 2 cases (22.2%) - stabilization. The median overall survival was 15.5 months.

Thus, the results of this study have shown high efficiency of drug therapy in the treatment of breast cancer patients with metastases in the brain.

1. Насхлеташвили Д. Р. Автореферат по теме кандидатской диссертации: «Современные возможности консервативного лечения больных раком молочной железы и мелкоклеточным раком легкого с метастазами в головной мозг». 2002 год, 36 страниц.

2. Насхлеташвили Д. Р., Горбунова В.А, Бекяшев А. Х., Москвина Е. А. Таргетная терапия в комплексном лечении больных раком молочной железы с гиперэкспрессией Her-2/neu и c метастатическим поражением головного мозга. Материалы мультидисциплинарного форума по лечению рака молочной железы, Санкт-Петербург, 24–25 октября 2013 года, абстракт, стр. 33.

3. Насхлеташвили Д. Р., Горбунова В. А., Москвина Е. А. Современные возможности таргетной терапии в лечении больных раком молочной железы с гиперэкспрессией Her-2/neu и с метастатическим поражением головного мозга. Вопросы онкологии, № 3, 2013 год, том 59, стр. 347–351.

4. Bendell JC, Domchek SM, Burstein HJ, et al: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97: 2972–2977, 2003 (иностранный источник).

5. Bezjak A, Adam J, Barton R et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002; 38: 487–496 (иностранный источник).

6. Burstein HJ, Lieberman G, Slamon DJ et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005; 16:1772–1777 (иностранный источник).

7. Chang E., Lob S. Diagnosis and Management of Central Nervous System Metastases from Breast Cancer. The Oncologist 2003, Vol. 8, No. 5, 398–410 (иностранный источник).

8. Christodoulou C, Bafaloukos D, Linardou H et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (HeCOG) phase II study. J Neurooncol 2005; 71: 61–65 (иностранный источник).

9. Cocconi G, Lottici R, Bisagni G et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990;8:327–334 (иностранный источник).

10. De la Monte SM, Hutchins GM, Moore GW: Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Am J Med 76:11–17, 1984 (иностранный источник).

11. Fabi A, Vidiri A, Ferretti G et al. Dramatic regression of multiple brain metastases from breast cancer with capecitabine: Another arrow at the bow? Cancer Invest 2006; 24: 466–468 (иностранный источник).

12. Franciosi V, Cocconi G, Michiara M et al., Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85: 1599–1605 (иностранный источник).

13. Gorbounova V. A., Bychkov M. B., Michina Z. P., Naskhletashvili D. R. Tеmozolomide in patients with brain metastases. 16th International Congress of Anti-Cancer Treatment (01–04/02/2005 г., Париж, Франция). Abstract book, стр. 306 (иностранный источник).

14. Heinrich B, Brudler O, Siekiera W, et al: Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab. Proc Am Soc Clin Oncol 22:37, 2003 (abstr 147) (иностранный источник).

15. Hikino H, Yamada T, Johbara K et al. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast 2006; 15: 97–99 (иностранный источник).

16. Khuntia D, Brown P, Li J et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 24: 1295–1304 (иностранный источник).

17. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608–3617 (иностранный источник).

18. Naskhletashvili D., Gorbounova V., Bychkov M., Bekyashev A., Karakhan V., Aleshin V., Moskvina E., Markovich A., Michina Z., Medvedev S. Targeted therapy (lapatinib and/or trastuzumab) and capecitabine in breast cancer (BC) patients with Her-2/neu overexpression and brain metastases (BM). EORTC-EANO-ESMO conference 2013 on trends in Central Nervous System Malignancies, Prague, 22–23 March 2013, abstract 164 (+ poster P.164) (иностранный источник).

19. Naskhletashvili D. R. Gorbunova V. A., Bychkov M. B., Chmutin G. E., Karahan V. B., Aloshin V. A., Moskvina E. A. Gemcitabine plus cisplatin in patients with heavily pretreated breast cancer with brain metastases. Journal of Clinical Oncology 28:7s, 2010 (suppl; abstr 1125) (иностранный источник).

20. Naskhletashvili D. R. Gorbunova V., Bychkov M., Rzaev D., Chmutin G., Karahan V., Aloshin V., Michina Z., Alieva S., Moskvina E. The role of temozolomide for patients with metastatic brain disease. Abstracts from the 9th meeting of the Europion Association of Neuro-Oncology, Maastricht, the Netherlands, September 16–19, 2010, p. 57–58 (иностранный источник).

21. Oberhoff C, Kieback DG, Wurstlein R et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: Results of a pilot study. Onkologie 2001; 24: 256–260 (иностранный источник).

22. Rosner D, Flower A, Lane W. Chemotherapy induces regression of brain metastases in breast carcinoma patients: update study. Proc Am Soc Clin Oncol 1993; 12: 508a (иностранный источник).

23. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986; 58: 832–839 (иностранный источник).

24. Samaan NA, Buzdar AU, Aldinger KA, et al: Estrogen receptor: A prognostic factor in breast cancer. Cancer 47:554–560, 1981 (иностранный источник).

25. Siegelmann-Danieli N, Stein M, Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 2003; 5: 833–834 (иностранный источник).

26. Tsao MN, Lloyd N, Wong R et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006;3: CD003869 (иностранный источник).

27. Wang ML, Yung WK, Royce ME et al. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 2001;24:421–424 (иностранный источник).

28. Wardley AM, Danson S, Clayton AJ, et al: High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center. Proc Am Soc Clin Oncol 21:61a, 2002 (abstr 241) (иностранный источник).

29. Weitzen R, Zach L, Kaufman B, et al: High incidence of brain metastasis in patients on trastuzumab for advanced breast cancer. Proc Am Soc Clin Oncol 21:316, 2002 (abstr 1936) (иностранный источник).